rna aptamers reversible antagonists coagulation factor ixa
many therapeutic agents associated adverse effects patients anticoagulants can engender acute complications significant bleeding increases patient morbidity mortality antidote control provides safest means regulate drug action reason despite known limitations toxicities heparin use remains high anticoagulant can controlled antidote polypeptide protamine- date generalizable strategy developing drug-antidote pairs described investigated whether drug-antidote pairs rationally designed taking advantage properties inherent nucleic acids make antidote-controlled anticoagulant agents show protein-binding oligonucleotides aptamers coagulation factor ixa potent anticoagulants also show oligonucleotides complementary aptamers can act antidotes capable efficiently reversing activity new anticoagulants plasma healthy volunteers patients tolerate heparin generalizable strategy rationally designing drug-antidote pair thus opens way developing safer regulatable therapeutics
